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doi:10.1016/j.jfma.2012.02.009Background/Purpose: XX male is a rare sex chromosomal disorder in infertile men. The
purpose of this study was to distinguish the clinical and genetic features of the 46,XX male
syndrome from other more frequent, testicular-origin azoospermic causes of male
infertility.
Methods: To study 46,XX male syndrome, we compared clinical and endocrinological param-
eters to other groups with testicular-origin azoospermia, and to an age-matched group of
healthy males and females as normal control. Fluorescent in situ hybridization for detection
and localization of the sex-determining region of the Y gene (SRY ), array-based comparative
genomic hybridization screening, and real-time qualitative polymerase chain reaction of
FGF9, WT1, NR5A1, and SPRY2 genes were performed in this genetic investigation.
Results: Our three patients with 46,XX male syndrome had a much higher follicular-
stimulating hormone level, lower body height, lower testosterone level, and ambiguous
external genitalia. One of the three patients with 46,XX male syndrome was SRY-negative.
A further genetic study, including a comparative genomic hybridization array and real-time
polymerase chain reaction, showed a gain of FGF9 copy numbers only in the SRY-negative
46,XX male. The genetic copy number of the FGF9 gene was duplicated in that case compared
to the normal female control and was significantly lower than that of the normal male
control. No such genomic gain was observed in the case of the two SRY-positive 46,XX males.of Gynecology and Obstetrics, Shin Kong Wu Ho-Su Memorial Hospital, 95 Wenchang Road, Shihlin 111,
org.tw (J.-L. Hwang).
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Cytogenic and molecular analyses of 46,XX male syndrome 73Conclusion: Similar to clinical manifestations of 46,XX male syndrome, genetic evidence in
this study suggests that FGF9 may contribute to sex reversal, but additional confirmation with
more cases is still needed.
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Chromosomal abnormalities are possible causes of male
subfertility and infertility. The overall incidence of chro-
mosome abnormalities in infertile men was estimated by
several studies to be around 5.8%,1 and 0.38% in newborns
delivered after successful intracytoplasmic sperm injection
procedures.2 Microdeletion of genes in the AZF area of the
Y chromosome is also a well-known etiology of azoospermia
and severe oligoasthenospermia in patients with male
infertility,3 and the overall frequency of microdeletions was
estimated in our series to be 12.2% in azoospermic men and
3.4% in oligozospermic men.4,5 Y-chromosome abnormali-
ties can be either numerical abnormalities or a variety of
structural aberrations. The total absence of the Y chro-
mosome may be seen as a molecularly visible defect by
a polymerase chain reaction (PCR) diagnosis and can be
proven by a cytogenic analysis of the chromosome
karyotype.6
During the screening of the 555 infertile male patients,
we found 47 cases of a Y chromosome gene deletion. Among
these patients, there were three cases for which we could
detect no genetic expression of the Y chromosome in the
PCR analysis. The cytogenetic analysis of the chromosome
revealed a 46,XX male karyotype. Furthermore, detection
and localization of the sex-determining region of the Y gene
(SRY ) can have a variable result.7e9 Two of the three cases
were found to have the SRY gene according to fluorescent
in situ hybridization (FISH), while the other case was
a 46,XX male who was SRY-negative. In addition to the
cytogenic and molecular analyses of 46,XX male syndrome,
this study also made clinical and endocrinological compar-
isons with other groups with testicular azoospermia such as
idiopathic hypogonadotropic hypogonadism (IHH) syndrome
and Klinefelter’s syndrome. The purpose of this study was
to distinguish the clinical and genetic features of the 46,XX
male syndrome from other, more frequently occurring
genetic disorders. The information can be a good reference
for counseling and treatment of male infertility.Materials and methods
Participants
In total, 47 patients screened from 555 infertile males were
found to have a microdeletion of the Y chromosome, and
three patients were found to have no Y chromosome
according to a PCR analysis. Among these 47 patients, 34
individuals were azoospermic and 13 were severely oligo-
zoospermic or asthenospermic.
In order to compare the clinical and endocrinological
features with those three cases with 46,XX male syndrome,13 cases of IHH and 31 cases of Klinefelter’s syndrome were
also selected from our 555 patients with male infertility (by
a post hoc approach).
DNA isolation and PCR analysis of microdeletions of
the Y chromosome
DNA was extracted from peripheral blood leukocytes of
patients, and genomic DNA was isolated using a Genomic
DNA Isolation Kit (PUREGENE, Madison, WI, USA) following
the manufacturer’s protocol. The concentration of the
isolated genomic DNA was determined by a spectrophoto-
metric analysis at 260 nm. All DNA samples were processed
for Yq microdeletions using a PCR. The STS and genes used
were as follows: AZFa: sY84 and sY86; AZFb: sY127 and
sY134; and AZFc: sY254 and sY255. SRY and ZFY were
included as internal controls.10
Cytogenetic analysis
Whole blood was collected, and plasma was prepared with
heparin. Peripheral blood lymphocytes were cultured in
two 25T flasks using RPMI media supplemented with 10%
fetal calf serum. Metaphase chromosomes were analyzed
by a standard Wright G-banding technique. Karyotyping was
performed in 50 metaphases by a conventional method.11
FISH for SRY detection and localization
The SRY probe, LSI SRY/CEPX, was obtained from Vysis
(Abbott Molecular Diagnostics, Hoofddorp, the
Netherlands). At room temperature, 7 ml of LSI hybridiza-
tion buffer, 1 ml of the LSI DNA probe, and 2 ml of purified
H2O were mixed, centrifuged for 1e3 seconds, vortexed,
then recentrifuged, heated for 5 minutes in a 73C water
bath, and placed on a slide warmer set to 45e50C.
Hybridization areas were marked with a diamond-tipped
scribe on a slide. The slide was immersed in a 73 1C
denaturing bath (70% formamide/2 SSC) for 5 minutes. If
the metaphase chromosome morphology was problematic,
a denaturing temperature of 70e73C possibly provided
better results. The slide was dehydrated for 1 minute in 70%
ethanol (EtOH), 1 minute in 85% EtOH, and 1 minute in 100%
EtOH. The slide was dried and placed on a 45e50C slide
warmer for 2 minutes. Ten microliters of probe mix was
applied to the slide. The coverslip was immediately applied
when the probe was placed on the slide, and was sealed
with diluted rubber cement. The slide was placed in a pre-
warmed humidified box, and hybridization was allowed to
proceed overnight for 12e16 h in a 37C incubator. One
wash tank with 0.4 SSC/0.3% NP-40 was prepared, and the
slide was placed in a 73 1C water bath for at least
74 H.-S. Chiang et al.30 minutes. A second tank of 2 SSC/0.1% NP-40 was
prepared at room temperature. The rubber cement seal
and coverslip were removed, and the slide was immediately
placed into a wash tank (0.4 SSC/0.3% NP-40), which was
agitated for 1e3 seconds. This was repeated for a maximum
of four slides, and then all slides were left in a Coplin jar for
2 minutes. The coverslips from several slides were not
removed before placing the slides in the wash bath. The
timing of incubation began when the last slide was added to
the wash bath. Slides were washed in 2 SSC/0.1% NP-40 at
room temperature for 5e60 seconds, with agitation for 1e3
seconds as a slide was placed in the bath. The slide was
allowed to air-dry in darkness. Ten microliters of DAPI II
counterstain was applied to the target area of the slide,
and a coverslip was added. The slide was viewed using
a suitable filter set, and then stored at e20C in the dark.12
Array-based comparative genomic hybridization
analysis using Affymetrix Genome Wide Human SNP
Array 6.0
Experiments were performed according to standard proto-
cols for the Affymetrix Genome Wide Human SNP Array 6.0
(Affymetrix Human SNP Assay 6.0 User’s Guide for Auto-
mated Target Preparation; Affymetrix, Santa Clara, CA,
USA). Quality control, genotype calling, probe-level
normalization, and raw microarray images were analyzed
using Affymetrix Genotyping Console Software vers.
3.0.1. Reference set 44 used related Han Chinese samples
obtained from the HapMap project. Genetic gains (with
a copy number of 3) and losses (with a copy number of
1) were defined according to the working criteria of the
Genotyping Console Software. To avoid false-positive
copy number changes due to random noise in the signal
intensity at each single-nucleotide polymorphism (SNP), we
set a minimum physical length of at least 10 consecutive
SNPs for putative genetic alterations. The physical positions
of all SNPs on the arrays were mapped according to the
Human Genome Sequence (http://www.ncbi.nlm.nih.gov/
genome/guide/human/; Build 36). To consider existing
structural variations of interest, we included public copy
number variation (CNV) data (http://projects.tcag.ca/
variation/) in our analysis.
Real-time qualitative PCR of the FGF9, WT1,
NR5A1, and SPRY2 genes
Multiples of changes in the FGF9, WT1, NR5A1, and SPRY2
gene copy numbers were determined by a quantitative PCR
using the LightCycler FastStart DNA MasterPLUS SYBR Green I
kit (Roche Molecular Systems, Branchburg, NJ, USA) and
LightCycler Instrument 1.5 (Roche Molecular Systems
Branchburg, NJ, USA). Quantification was performed by
comparing the target locus to the reference ATP2B4 gene.
Relative quantities of copy numbers of the FGF9, WT1,
NR5A1, and SPRY2 genes were normalized using Promega
Human Genomic DNA: Female (Promega, Madison, WI, USA)
as a calibrator. Cycling conditions were as follows: pre-
incubation at 95C for 10 minutes followed by 40 cycles of
95C for 10 seconds, 60C for 15 seconds, and 72C for 10
seconds. The specific oligonucleotide primer pairs wereselected from the Universal Probe Library (Roche Molecular
Systems), and the specificity of each primer pair was veri-
fied. The mean threshold cycle number (Ct) for each gene
in each sample was obtained from triplicate experiments.
The primers were WT1, 50-aggaggatagcacggaagaa-30 and 50-
cagttccccaaccactcatt-30; NR5A1, 50-gtccctcctcctcctaaa-30
and 50-aatgaatgaatgggcaaagg-30; FGF9, 50-aaaagccgag
tcctctgatg-30 and 50-cccaggtggtcacttaacaaa-30; SPRY2,
50-agatcagagccatccgaaac-30 and 50-ctctcgtgtttgtgctgagtg-30;
and ATP2B4, 5
0-ccacgaacaccactcctg-30 and 50-accctagtcc-
caaacttagaagcc-30.
Statistical analysis
Statistical analysis was performed using SAS vers. 8 (SAS
Institute, Cary, NC, USA). A Z-test was used to test the two
proportions between both the AZFb- and AZFc-deletion
group and the AZFc-only-deletion group. A t-test was used
to test differences among the body height (BH), follicle-
stimulating hormone (FSH), and testosterone concentration
of patients andnormal controls. Significancewasacceptedat
p< 0.05.
Results
We performed a cytogenic analysis of the 47 patients with
a PCR molecular diagnosis of Y chromosome micro-
deletions, including three patients whose entire Y chro-
mosome could not be identified. In these three patients
with the complete absence of the Y chromosome on PCR
screening, evaluation of the G-banded chromosome prep-
aration from phytohemagglutinin-stimulated lymphocytes
revealed a 46,XX karyotype. Cytogenetic studies confirmed
a nonmosaic karyotype in all metaphases analyzed. The
presence of the SRY gene was confirmed by PCR. Seven of
the 11 patients (63.6%) with AZFb and AZFc area deletions
were found to have variable Y chromosome abnormalities,
whereas only five of 31 patients (16.1%) with AZFc area
deletions were found to have chromosomal abnormalities.
The Y chromosome had higher rates of cytogenic anomalies
when the deletion area was found to be larger in the PCR
analysis (pZ 0.0008) (Table 1).
Clinically, there were no remarkable variabilities in
physical characteristics; the genitals were normal among
the different groups with microdeletions of the Y chromo-
some. However, the general feature of patients with 46,XX
male syndrome was quite unusual, even though they were
completely masculinized. Their average body height
(160.3 cm) was significantly less than that of the aged-
matched 46,XY healthy male controls of a normal pop-
ulation (171.8 cm, pZ 0.048). They were also significantly
shorter than the group of males with AZFb and AZFc dele-
tions (172.6 cm, pZ 0.02), Kleinefelter’s syndrome males
(175.9 cm, pZ 0.01), and males with IHH (Table 2).
The three cases of 46,XX male syndrome also had
prominent clinical features of atrophic testicles and
ambiguous external genitalia. One had cryptorchism, and
another had hypospadia (Table 3). Their endocrinological
picture reflected remarkable testicular atrophy. Elevation
of the FSH level of 46,XX males was even more prominent
than that of patients with Kleinefelter’s syndrome
Table 1 Variable chromosomal abnormalities in the molecular and cytogenetic screening of the 47 patients with Y chromo-
some gene deletion (including 3 patients with total absence of Y chromosome).
Group Microdeletion of Y chromosome
by PCR molecular diagnosis
N Cytogenic analysis of abnormal
chromosome karyotype
n Sum of patients with abnormal
karyotype for each group (n/N  100) %
1 Cannot detect the entire
AZF region of Y chromosome
3 46,XX 3 3 (100)
2 Both AZFb and AZFc deletion 11 46,X,þmar 2 7 (63.6)a
46,X,del (Y) (q11.22) 2
mos 45,X/46,XY 1
mos 46,X,idic(Y)(q11.22)/45,X 1
47,XY,þmar 1
3 Only AZFb deletion 2 d 0 0 (0)
4 Only AZFc deletion 31 46,X,del (Y) (q11.22) 1 5 (16.1)
46,XY,inv(15) 1
46,XY,inv(9qh) 1
46,XY,9qhþ 1
46,X,Yqhe 1
Total 47 15 15 (31.9)
a Z-test was used to test the two proportions between group 2 and group 4 (pZ 0.0008). The significance level was set at p < 0.05.
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differentiated between groups with 46,XX male Kleinefel-
ter’s syndrome and IHH in a state of untreated hypo-
gonadism (Table 2).
Cytogenetic studies confirmed a nonmosaic 46,XX
karyotype in the three cases. Two of them were identified
to possess the SRY gene by FISH; one case had no signal for
the SRY gene (Fig. 1). For the case of the 46,XX male that
was SRY-negative, we performed a further array-based
comparative genomic hybridization (array-CGH) analysis
and validated the CNVs. Duplication of the FGF9 and SPRY2
genes was detected (Fig. 2). Real-time PCR analysis with
multiple controls confirmed significant differences in these
two genes in the SRY-negative 46,XX male (Fig. 3).Discussion
46,XX male syndrome represents a rare, poorly characterized
form of male hypogonadism in the literature. By 1996, only
150 patients with classical XX male syndrome had been re-
ported13; however,more than 100 caseswere described in the
next 10 years (1996e2006).14 Some of the newly foundTable 2 BH, hormonal comparison among the groups of 46,XX
AZFc,47,XXY, IHH and healthy individuals.
(1) (2) (3
46,XX
male (nZ 3)
Normal
male
Norma
femal
BH (cm) 160.3 4.5 171.8a 158.9
FSH (mIU/mL) 54.8 8.9 1.7e11 3.9e1
Testosterone (ng/mL) 1.88 0.39e 2.5e8.5 0.06e
The level of significance of the t-test was set at p  0.05.
a BH: (1) versus (2), (4), (5), p  0.05.
b BH: (2) versus (5), p  0.05.
c FSH: (1) versus (4), (6), p  0.05.
d FSH: (4) versus (5), p  0.05.
e Testosterone: (2) versus (1), (4), (5), p  0.05.patients were in the neonatal stage15 with genital ambiguities
andwere detected by a chromosomal screening analysis. As in
this study, increasing numbers of cases were detected in
groups with male infertility, especially among patients diag-
nosed with testicular azoospermia.16 This means that 46,XX
males are veryoftenphenotypicallymale. Their social life and
daily life are normal as a man until they discover the problem
of infertility. Although this genetically belongs to a compli-
cated mechanism of female-to-male sex reversal in the pre-
gonadal stage, a 46,XX male or 46,XX sex reversal was
reasonably renamed a 46,XX testicular disorder17 of sex
development based on clinical manifestations.
Usually, we perform a PCR analysis to detect micro-
deletions of the Y chromosome, and a cytogenetic analysis
of the chromosome karyotype for all patients with azoo-
spermia or severe oligozoospermia of testicular origin.
46,XX male syndrome patients are detected as a group with
the greatest severity of defects or the entire loss of the Y
chromosome. Among the three groups with variable
microdeletions of the Y chromosome (46,XX, AZFb þ AZFc
deletion, and only the AZFc deletion), a higher prevalence
of an abnormal chromosome karyotype was found in
patients with a wider microdeletion of the Y chromosomemales, microdeletion of Y chromosome with AZFb and/or
) (4) (5) (6)
l
e
AZFb and/or
AZFc (nZ 30)
47,XXY
(nZ 31)
IHH
(nZ 8)
172.6 6a 175.9 6.1a,b 170.3 10.1
0 14.6 7.6c 39.5 10.3d 1.7 1.3c
0.86 3.79 1.73e 1.68 1.53e 2.8 4.2
Table 3 SRY and other related component determination, localization, and clinical relevance of three patients with the 46,XX
male syndrome.
PID Age SRY Localization Testis and external
genital organs
Virilization Sperm
sample
FSH
(mIU/mL)
LH
(mIU/mL)
Testosterone
(ng/mL)
Prolactin
(ng/mL)
M1 33 þ X
chromosome
Left :1.0 cm þ Azoospermia 46.58 17.63 2.03 27.05
Right: <0.5 cm
M2 34 þ Not
investigated
Left: cryptochirm þ Azoospermia 54.33 19.57 2.17 8.15
Right :0.8 cm
(migrating)
M3 52   Left: <0.5 cm,
glandular hypospadia
Right : <0.5cm
þ Azoospermia 64.31 20.16 1.44 16.08
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cytogenic analysis, 12 patients had structural anomalies of
the Y chromosome. Patients with the Y chromosome
structural anomaly in combination with variable Y chro-
mosome microdeletions had a statistically significant
(p< 0.05) higher prevalence of azoospermia (10/12, 83%)
compared to those with no structural anomalies (20/32,
62.5%). However, patients with loss of the entire Y chro-
mosome (46,XX male syndrome) had completely different
clinical features compared to patients with structural
anomalies that occurred in only certain fragments of the Y
chromosome. This indicates that through the pathogenesis
of sex reversal, phenotypic changes of 46,XX male
syndrome go beyond loss of function of the Y chromosome.
All three patients with 46,XX male syndrome had total
azoospermia with atrophic testes and highly elevated FSH
and lower testosterone levels. In groups with severe
microdeletions in the variable AZFb or AZFb þ AZFc areas of
the Y chromosome, only 30.7% (4/13) had atrophic testes,Figure 1 Fluorescent in situ hybridization (FISH) with the LSI
SRY (orange)/CEP X (green) probes. No orange signal corre-
sponding to the SRY gene was detected at all chromosomes but
two green signals corresponding to the centromeric region of
both chromosome X.
Figure 2 Array-based comparative genomic hybridization
(array-CGH) profiles are shown for an SRY-negative 46,XX male
patient. The Y-axis marks the intensity ratios plotted on a log2
scale. The X-axis shows the chromosome coordinate in mega-
bases (Mb). (A) FGF9 gene. The duplicated 13q12.11 region
(21.143874e21.174184 Mb) is marked with a circle. (B) SPRY2
gene. The duplicated 13q31.1 region (79.807500e79.813700
Mb) is marked with a circle.
Figure 3 The real-time quantitative PCR (qPCR) results for four sex-determining related genes (FGF9, SPRY2, WT1, NR5A1). P1,
46,XX,SRY(e); P2, 46,XX,SRY(þ); P1s, the sister of the P1. The fold change in gene copy number for the target gene relative to the
endogenous reference gene (ATP2B4) was compared for the patients (P1eP2) and the control DNA (P1s, N1eN10) as described in
the Materials and methods section. The normalized fold changes were interpreted as follows: no change (0.7e1.4, white bar),
homozygous loss (<0.3, black bar), over-representation (>1.4, black bar), and ambiguous (0.3e0.7, gray bar).
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normal testosterone levels, and FSH levels were dependent
on the width of the microdeletion; however, on average,
they were normal or borderline and significantly lower than
those of patients with 46,XX male syndrome. This clearly
shows that deletion of the AZF area of the Y chromosome in
46,XX male syndrome is the cause of the defects in sper-
matogenesis. The X chromosome inactivation mechanism
can disrupt normal SRY expression.18 The SRY gene might
not be sufficient to induce adequate function of Sertoli’s
cells in XX (SRYþ) mice,19 and a complete Sertoli’s cell-only
syndrome and hyperplasia of Leydig cells were found in
other studies of 46,XX males with testicular biopsies.20 In
our case of the 46,XX male who was SRY(e), we found that
the genetic copy number of FGF9 was duplicated,
compared to the normal female control. However, it was
significantly lower than that of the normal male control.
The function of the FGF9 gene was recently confirmed to be
correlated with postnatal testicular development.
Complete testicular atrophy of 46,XX males should theo-
retically occur through some pathogenesis of the sex-
reversal mechanism.
Compared to the age-matched group of healthy males in
the normal population, our three patients with 46,XX male
syndrome had a higher FSH level, lower body height, lower
testosterone level, and ambiguous external genitalia. The
body height of 46,XX males was also significantly lower than
that of the other male groups with chromosomal anomalies.
Patients with 47,XXY are much taller than normal males and46,XX males can be supported by the existence of a Y-linked
growth gene.21,22 46,XX males were even shorter than
patients with IHH, and their body height was close to that of
normal females, which might indicate that hypogonadism
contributes less to growth. The Y-linked growth gene cannot
be switched to 46,XXmales in the early sex-reversal process,
which might cause them to exhibit a female stature.
Previous studies showed that patients with classical 46,XX
male syndrome have normal-for-age testosterone levels
during puberty but frequently exhibit hypergonadotropic
hypogonadism in adulthood.23 The average serum testos-
terone level of our three 46,XXmale patients (1.88 0.39 ng/
mL) was lower than normal values (2.5e8.5 ng/mL), but not
significantly lower than that of patients with Klinefelter’s
syndrome or patients with hypogonadotropic hypogonadism.
All three patients acted as healthy adult males in society with
no symptoms of male hypogonadism. One of them had bilat-
eral mal-descended testicles, and one had hypospadia, but
none had gynecomastia. This means that the lower levels of
testosterone that affected our three patients with 46,XX
male syndrome was limited, variable, and independent of
their serum testosterone levels (Table 3).24 The clinical and
endocrinological profiles of our three cases with 46,XX males
may also be evidence to support the genetic function of sex
reversal in the embryological stage.
One of our three patients with 46,XX male syndrome was
SRY-negative. Even though the hormone profile of this SRY-
negative 46,XX male was more prominent as a picture of
hypertrophic hypogonadism than that of the other two SRY-
78 H.-S. Chiang et al.positive 46,XX males (Table 3), we could find no significant
difference in clinical manifestations as described in
a previous report.25 Furthermore, our epigenetic study
showed a gain in FGF9 copy numbers in the SRY-negative
46,XX male. No such genomic gain was observed in the case
of the SRY-positive 46,XX male.26,27 Furthermore, the copy
number of the SPRY2 gene in our SRY-negative 46,XX male
patient was higher than that of the SRY-positive 46,XX
male, as well as higher than those of the tested normal
males and females. In the literature, the SPRY2 gene is
involved in male sex organogenesis by controlling FGF9
gene-induced mesonephric cell migration to the developing
testis.28 The higher amount of SPRY2 in this SRY-negative
46,XX male may have some meaning combined with the
higher amount of FGF9. The higher amount of FGF9 inter-
feres with the expression of WNT4 in the embryo, thereby
retarding ovarian development of 46,XX males, even in the
absence of the SRY gene.28,29 Additional screening of 46,XX
males is needed to elucidate the role of FGF9 and other
genetic mechanisms of sex reversal.
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